MCID: CRB025
MIFTS: 46

Carbohydrate Metabolic Disorder malady

Categories: Metabolic diseases

Aliases & Classifications for Carbohydrate Metabolic Disorder

Aliases & Descriptions for Carbohydrate Metabolic Disorder:

Name: Carbohydrate Metabolic Disorder 12 14
Carbohydrate Metabolism, Inborn Errors 42 69
Disorder of Carbohydrate Metabolism 29 69
Disorder of Carbohydrate Transport and Metabolism 12
Inborn Errors of Carbohydrate Metabolism 12
Inborn Carbohydrate Metabolism Disorder 12
Carbohydrate Metabolism Disorders 41
Carbohydrate Metabolism Disorder 52

Classifications:



External Ids:

Disease Ontology 12 DOID:2978
ICD9CM 35 271.8
MeSH 42 D002239
ICD10 33 E74 E74.8

Summaries for Carbohydrate Metabolic Disorder

MedlinePlus : 41 metabolism is the process your body uses to make energy from the food you eat. food is made up of proteins, carbohydrates, and fats. chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. your body can use this fuel right away, or it can store the energy in your body tissues. if you have a metabolic disorder, something goes wrong with this process. carbohydrate metabolism disorders are a group of metabolic disorders. normally your enzymes break carbohydrates down into glucose (a type of sugar). if you have one of these disorders, you may not have enough enzymes to break down the carbohydrates. or the enzymes may not work properly. this causes a harmful amount of sugar to build up in your body. that can lead to health problems, some of which can be serious. some of the disorders are fatal. these disorders are inherited. newborn babies get screened for many of them, using blood tests. if there is a family history of one of these disorders, parents can get genetic testing to see whether they carry the gene. other genetic tests can tell whether the fetus has the disorder or carries the gene for the disorder. treatments may include special diets, supplements, and medicines. some babies may also need additional treatments, if there are complications. for some disorders, there is no cure, but treatments may help with symptoms.

MalaCards based summary : Carbohydrate Metabolic Disorder, also known as carbohydrate metabolism, inborn errors, is related to galactose epimerase deficiency and pyruvate dehydrogenase e1-alpha deficiency. An important gene associated with Carbohydrate Metabolic Disorder is INS (Insulin), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Insulin Glargine and Insulin Lispro have been mentioned in the context of this disorder. Affiliated tissues include testes and thyroid, and related phenotypes are Increased transferrin (TF) endocytosis and Apoptosis resistance

Disease Ontology : 12 An inherited metabolic disorder that affect the catabolism and anabolism of carbohydrates.

Related Diseases for Carbohydrate Metabolic Disorder

Diseases related to Carbohydrate Metabolic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Related Disease Score Top Affiliating Genes
1 galactose epimerase deficiency 30.0 GALK1 GALT
2 pyruvate dehydrogenase e1-alpha deficiency 11.1
3 galactosemia 11.1
4 fructose-1,6-bisphosphatase deficiency 11.1
5 pentosuria 11.1
6 mucopolysaccharidosis ii 10.8
7 congenital disorder of deglycosylation 10.8
8 congenital disorder of glycosylation, type in 10.8
9 hyperinsulinemic hypoglycemia 10.8
10 glucosephosphate dehydrogenase deficiency 10.8
11 familial monosomy 7 syndrome 10.2 GALK1 GALT
12 amelogenesis imperfecta, type ig 10.2 GALK1 GALT
13 hyperphenylalaninemia, bh4-deficient, b 10.2 G6PC PYGM
14 leukemia, acute lymphoblastic 3 10.2 G6PC GALK1 GALT
15 glycogen storage disease iv 10.2
16 spinal muscular atrophy, lower extremity-predominant, 2, ad 10.1 AGL ALDOB G6PC
17 alopecia-mental retardation syndrome 2 10.1 ABCC8 G6PC INS
18 autoimmune disease 1 10.1 ABCC8 INS PYGM
19 neurogenic arthropathy 10.1 ABCC8 G6PC INS
20 tropical sprue 10.1 ALDOB LCT
21 renal glucosuria 10.1
22 labyrinthine unilateral reactive loss 10.0 ABCC8 INS
23 atrial fibrillation, familial, 4 10.0 AGL BTD HLCS
24 pili torti developmental delay neurological abnormalities 10.0 PFKM PYGM
25 bardet-biedl syndrome 3 10.0 AGL G6PC GAA GBE1
26 peroneal neuropathy 10.0 ABCC8 G6PC INS
27 stickler syndrome, type ii 10.0 AGL G6PC GAA GBE1
28 neuronopathy, distal hereditary motor, type vi 10.0 GAA PFKM PYGM
29 brain stem glioma 10.0 ABCC8 G6PC INS
30 hypogonadism 10.0 G6PC INS PFKM
31 muscular dystrophy, limb-girdle, type ic 9.9 BTD HLCS
32 native american myopathy 9.9 GBE1 PFKM PYGM
33 pyruvate carboxylase deficiency 9.9
34 fructose intolerance 9.7
35 pepck 1 deficiency 9.7
36 lacticacidemia due to pdx1 deficiency 9.7
37 glycogen storage disease due to lactate dehydrogenase deficiency 9.7
38 pyruvate carboxylase deficiency, benign type 9.7
39 pyruvate dehydrogenase e2 deficiency 9.7
40 pyruvate carboxylase deficiency, infantile form 9.7
41 pyruvate carboxylase deficiency, severe neonatal type 9.7
42 galactokinase deficiency with cataracts 9.7
43 generalized galactose epimerase deficiency 9.7
44 erythrocyte galactose epimerase deficiency 9.7
45 fructosuria, essential 9.7
46 pyruvate dehydrogenase e1-beta deficiency 9.7
47 mitochondrial pyruvate carrier deficiency 9.7
48 dihydrolipoamide dehydrogenase deficiency 9.7
49 pyruvate dehydrogenase phosphatase deficiency 9.7
50 alexander disease 9.7 AGL ALDOB G6PC GALK1 GBE1 PHKA2

Graphical network of the top 20 diseases related to Carbohydrate Metabolic Disorder:



Diseases related to Carbohydrate Metabolic Disorder

Symptoms & Phenotypes for Carbohydrate Metabolic Disorder

GenomeRNAi Phenotypes related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased transferrin (TF) endocytosis GR00363-A 9.36 AGXT ALDOB G6PC GAA GALK1 GALT
2 Apoptosis resistance GR00093-A-0 9.13 G6PC PFKM PHKA2

MGI Mouse Phenotypes related to Carbohydrate Metabolic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ABCC8 AGL AGXT BTD G6PC GAA
2 liver/biliary system MP:0005370 9.63 INS PMM2 AGL ALDOB G6PC GBE1
3 muscle MP:0005369 9.56 AGL BTD GAA GBE1 INS PFKM
4 renal/urinary system MP:0005367 9.1 AGXT BTD G6PC INS PMM2 PYGM

Drugs & Therapeutics for Carbohydrate Metabolic Disorder

Drugs for Carbohydrate Metabolic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 845)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 160337-95-1
2
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 133107-64-9
3
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
4
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
6
Metyrapone Approved Phase 4 54-36-4 4174
7
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
8
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
9
Atenolol Approved Phase 4 29122-68-7 2249
10
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 111025-46-8 4829
11
Ethanol Approved Phase 4,Phase 2 64-17-5 702
12
Diazoxide Approved Phase 4,Phase 2 364-98-7 3019
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
14
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
15
Febuxostat Approved Phase 4,Phase 3 144060-53-7 134018
16
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
17
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
18
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
19 Parecoxib Approved Phase 4 198470-84-7
20
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
21
lanreotide Approved Phase 4 108736-35-2
22
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 383414 6400441
23
Somatostatin Approved Phase 4,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
24
Saxagliptin Approved Phase 4,Phase 3,Phase 2 361442-04-8 11243969
25
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
26
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
27 Moxonidine Approved Phase 4 75438-57-2 4810
28
Spironolactone Approved Phase 4,Phase 1,Early Phase 1 1952-01-7, 52-01-7 5833
29
Allopurinol Approved Phase 4,Phase 3,Early Phase 1 315-30-0 2094
30
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
31
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
32
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
33
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1 2216-51-5 16666
34
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
35
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3 50-18-0, 6055-19-2 2907
36
Glycerol Approved, Experimental Phase 4,Phase 3,Phase 2,Early Phase 1 56-81-5 753
37
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
38
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
39
Ritonavir Approved, Investigational Phase 4,Phase 1 155213-67-5 392622
40
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
41
rituximab Approved Phase 4,Phase 2,Phase 1 174722-31-7 10201696
42
Primaquine Approved Phase 4,Phase 1 90-34-6 4908
43
Dapsone Approved, Investigational Phase 4 80-08-0 2955
44
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 141758-74-9 15991534
45
Pramlintide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 151126-32-8
46
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2 135062-02-1 65981
47
Glimepiride Approved Phase 4,Phase 3,Phase 2 93479-97-1 3476
48
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
49
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
50
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 2 56180-94-0 441184

Interventional clinical trials:

(show top 50) (show all 2472)
id Name Status NCT ID Phase
1 CPAP for Infantile Pompe Disease Unknown status NCT02405624 Phase 4
2 Mechanisms Underlying Postoperative Insulin Resistance and Inflammation Unknown status NCT01470534 Phase 4
3 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
4 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
5 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4
6 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4
7 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4
8 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4
9 Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Unknown status NCT00259168 Phase 4
10 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
11 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4
12 How Does the Diabetes Drug, Pioglitazone, Reduce Protein Loss in the Urine? Unknown status NCT00749047 Phase 4
13 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
14 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
15 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4
16 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4
17 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4
18 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
19 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
20 Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy Unknown status NCT01070758 Phase 4
21 The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control Unknown status NCT00282659 Phase 4
22 Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4
23 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4
24 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
25 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
26 Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4
27 Late-Onset Treatment Study Extension Protocol Completed NCT00455195 Phase 4
28 High Dose or High Dose Frequency Study of Alglucosidase Alfa Completed NCT00483379 Phase 4
29 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease Completed NCT00144781 Phase 4
30 Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy Completed NCT00607386 Phase 4
31 A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Completed NCT00299000 Phase 4
32 A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients Completed NCT00144768 Phase 4
33 Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior Completed NCT02406469 Phase 4
34 Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People Completed NCT02878876 Phase 4
35 Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance Completed NCT02636413 Phase 4
36 Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Completed NCT02405598 Phase 4
37 Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa Completed NCT01288027 Phase 4
38 An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Completed NCT00701129 Phase 4
39 Safety and Tolerability of Low Dose Primaquine Completed NCT02434952 Phase 4
40 Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency Completed NCT00243542 Phase 4
41 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed NCT01988402 Phase 4
42 Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children Completed NCT01766310 Phase 4
43 Glucagon Efficiency After High and Low Carbohydrate Diet Completed NCT02578498 Phase 4
44 Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women Completed NCT01628705 Phase 4
45 The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway Completed NCT00755729 Phase 4
46 Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery Completed NCT01774084 Phase 4
47 Effect of Preoperative Supplementation in Insulin Resistance Completed NCT00657124 Phase 4
48 The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes Completed NCT00950677 Phase 4
49 How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics Completed NCT00667732 Phase 4
50 Pizza-Salami Study in Children and Adolescents With Type 1 Diabetes Completed NCT01400659 Phase 4

Search NIH Clinical Center for Carbohydrate Metabolic Disorder

Cochrane evidence based reviews: carbohydrate metabolism, inborn errors

Genetic Tests for Carbohydrate Metabolic Disorder

Genetic tests related to Carbohydrate Metabolic Disorder:

id Genetic test Affiliating Genes
1 Disorder of Carbohydrate Metabolism 29

Anatomical Context for Carbohydrate Metabolic Disorder

MalaCards organs/tissues related to Carbohydrate Metabolic Disorder:

39
Testes, Thyroid

Publications for Carbohydrate Metabolic Disorder

Articles related to Carbohydrate Metabolic Disorder:

id Title Authors Year
1
Protective effects of vescalagin from pink wax apple [Syzygium samarangense (Blume) Merrill and Perry] fruit against methylglyoxal-induced inflammation and carbohydrate metabolic disorder in rats. ( 23819528 )
2013
2
Hashimoto's thyroiditis and carbohydrate metabolism disorders in patients hospitalised in the Department of Endocrinology and Diabetology of Ludwik Rydygier Collegium Medicum in Bydgoszcz between 2001 and 2010. ( 22378092 )
2012
3
[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension]. ( 15759454 )
2005
4
[Diagnostic criteria of carbohydrate metabolism disorders in pulmonary tuberculosis complicated by diabetes mellitus in patients with various haptoglobin phenotypes]. ( 11338533 )
2001
5
[Carbohydrate metabolic disorder in women with a neuroendocrine syndrome]. ( 8017575 )
1994
6
[Glycosylated proteins and the rheological properties of the erythrocytes in carbohydrate metabolic disorders]. ( 1803588 )
1991
7
Autotransplantation of pancreatic tail tissue to prevent carbohydrate metabolic disorder following total pancreatectomy. A case report with preliminary experience. ( 6816515 )
1982

Variations for Carbohydrate Metabolic Disorder

Expression for Carbohydrate Metabolic Disorder

Search GEO for disease gene expression data for Carbohydrate Metabolic Disorder.

Pathways for Carbohydrate Metabolic Disorder

Pathways related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 12)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 ABCC8 AGL AGXT ALDOB ALG6 BTD
2
Show member pathways
12.45 AGL ALDOB G6PC GAA GALK1 GALT
3
Show member pathways
12.44 AGL ALDOB G6PC GAA GBE1 PFKM
4
Show member pathways
11.72 G6PC INS PYGM
5 11.68 G6PC PHKA2 PYGM
6
Show member pathways
11.64 ABCC8 INS PHKA2
7
Show member pathways
11.52 GALK1 GALT PMM2
8
Show member pathways
11.36 AGL G6PC GAA GALK1 GALT GBE1
9 11.31 ABCC8 ALDOB G6PC INS
10
Show member pathways
11.28 ALDOB PFKM PMM2
11 11.18 AGL GBE1 PHKA2 PYGM
12 9.88 BTD HLCS

GO Terms for Carbohydrate Metabolic Disorder

Biological processes related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.8 AGL GAA GALK1 HLCS LCT PFKM
2 glycogen metabolic process GO:0005977 9.63 AGL G6PC GAA GBE1 PHKA2 PYGM
3 glucose homeostasis GO:0042593 9.61 G6PC INS PFKM
4 carbohydrate metabolic process GO:0005975 9.61 AGL GAA GALK1 GALT GBE1 INS
5 glycogen biosynthetic process GO:0005978 9.51 AGL GBE1
6 canonical glycolysis GO:0061621 9.49 ALDOB PFKM
7 carbohydrate phosphorylation GO:0046835 9.48 GALK1 PFKM
8 muscle cell cellular homeostasis GO:0046716 9.46 GAA PFKM
9 biotin metabolic process GO:0006768 9.4 BTD HLCS
10 galactose metabolic process GO:0006012 9.37 GALK1 GALT
11 galactose catabolic process GO:0019388 9.32 GALK1 GALT
12 glycogen catabolic process GO:0005980 9.1 AGL G6PC GAA PFKM PHKA2 PYGM

Molecular functions related to Carbohydrate Metabolic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.86 AGL AGXT ALG6 GALK1 GALT GBE1
2 transferase activity, transferring glycosyl groups GO:0016757 9.62 AGL ALG6 GBE1 PYGM
3 hydrolase activity, acting on glycosyl bonds GO:0016798 9.54 AGL GAA LCT
4 phosphotransferase activity, alcohol group as acceptor GO:0016773 9.4 G6PC GALK1
5 catalytic activity GO:0003824 9.35 GAA HLCS LCT PFKM PYGM
6 fructose binding GO:0070061 9.16 ALDOB PFKM
7 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004553 8.8 GAA GBE1 LCT

Sources for Carbohydrate Metabolic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....